Apyx Medical Corp (APYX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Form 10-Q for Apyx Medical Corp for the quarterly period ended March 31, 2026. Apyx is a surgical aesthetics company focused on Helium Plasma Platform Technology products, including Renuvion, J-Plasma, and the AYON Body Contouring System. The company operates two primary segments: Surgical Aesthetics and OEM (Original Equipment Manufacturer).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $12.49 million | $9.43 million |
| Gross Profit | $7.93 million | $5.67 million |
| Gross Margin | 63.5% | 60.1% |
| Net Loss (Attributable to Stockholders) | $(2.11) million | $(4.15) million |
| Loss Per Share (Basic & Diluted) | $(0.05) | $(0.10) |
| Cash and Cash Equivalents | $31.14 million | $31.01 million |
| Long-Term Debt (Net) | $35.09 million | $34.85 million |
| Working Capital | $45.35 million | $46.77 million |
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 32.4% year-over-year. The Surgical Aesthetics segment drove this growth with a 36.1% increase, attributed to the commercial launch of the AYON system, increased international generator sales, and higher handpiece volume. International sales grew 62.9% to $4.38 million.
- Profitability Improvement: The net loss narrowed significantly by 49.2% compared to Q1 2025. Gross margin expanded to 63.5% due to a favorable product mix shift toward higher-margin Surgical Aesthetics products.
- Expense Management: Research and development expenses decreased 4.9%, and professional services declined 9.0%. However, salaries and related costs rose 5.6% due to increased compensation for existing employees.
- Cash Flow: Net cash used in operating activities improved to $0.57 million from $0.70 million in the prior year, driven by the reduced operating loss.
Outlook, Risks, and Management Commentary
- Product Pipeline: The company submitted a 510(k) premarket notification to the FDA for the AYON Body Contouring System to include power liposuction, anticipating clearance in Q2 2026.
- Market Dynamics: Management notes that while GLP-1 receptor agonists (e.g., Wegovy, Ozempic) initially impacted cosmetic surgery demand, the resulting loose skin from rapid weight loss is expected to drive demand for body contouring procedures, benefiting Renuvion sales.
- Liquidity and Debt: The company maintains a $37.5 million term loan with Perceptive Credit Holdings. As of March 31, 2026, the company was in compliance with financial covenants, which include trailing twelve-month revenue targets for the Surgical Aesthetics segment ($52.4 million for 2026) and a maximum operating expense target of $45.0 million for 2026.
- Legal Contingencies: The company faces product liability lawsuits regarding off-label use and marketing. Management has accrued estimated losses of approximately $1.45 million for one set of cases and $1.30 million for another, with a reasonable possibility of additional losses that cannot currently be estimated.
- China Joint Venture: The company's 51% owned China JV is consolidated as a Variable Interest Entity (VIE). The JV commenced operations in Q2 2025.
Investor Verification Checklist
- Verify the timeline and success of the pending FDA 510(k) clearance for the AYON power liposuction label expansion.
- Monitor compliance with the Perceptive Credit Agreement covenants, specifically the $52.4 million Surgical Aesthetics revenue target for 2026.
- Assess the potential financial impact of ongoing product liability litigation and insurance coverage deductibles.
- Track the trajectory of OEM segment revenue, which management expects to decrease as focus shifts to Surgical Aesthetics.
- Review the impact of GLP-1 drug adoption on the broader cosmetic surgery market and Apyx's specific handpiece sales volume.